Vesselon, Inc.

Nov 1

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals

By Clayton Larsen — President & CEO, Vesselon, Inc. Eli Lilly’s recent acquisition of Point Biopharma steps the market closer to wider adoption of radiopharmaceuticals for cancer therapy. Perhaps surprising to some, sonicated microsphere technology, like that being pioneered by Vesselon, has already been demonstrated to radiosensitize cancer cells to…

Drug Delivery

4 min read

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals

Drug Delivery

4 min read

Oct 5

How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates

By Clayton Larsen — President & CEO, Vesselon, Inc. ADC’s are an exciting new class of drugs that offers clinical benefits to a wide range of cancers. Unlike immune modulating monoclonal antibodies (mAbs) such as checkpoint inhibitors, the mAb role in an ADC serves as a carrier and targeting agent…

Drug Delivery

4 min read

How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates

Drug Delivery

4 min read

Aug 24

Webinar: How Biophysics Can Change the Receive Characteristics of Characteristics of Tumors

Webinar: How Biophysics Can Change the Receive Characteristics of Characteristics of Tumors It is believed that interstitial fluid pressure and solid stress are major obstacles preventing efficient delivery of macromolecules into tumor tissue, as well as stroma and an immunosuppressive tumor microenvironment. One promising solution is to modulate the tumor microenvironment with biophysics using a combination of gas microspheres and ultrasound…

3 min read

Jul 5

Harnessing Sonoporation and Lipid Encapsulation: Vesselon’s Breakthrough in Drug Delivery

By Clayton Larsen — President & CEO, Vesselon, Inc. The pharmaceutical landscape is poised for significant transformation with Vesselon’s latest innovative platform. Through a unique approach that enhances the receptivity of targeted cells and tissues, Vesselon departs from conventional pharmaceutical methods. The innovation lies in Vesselon’s proprietary TriForm™ technology, which…

Drug Delivery

1 min read

Drug Delivery

1 min read

Jun 30

Limits of Keytruda?

By Clayton Larsen — President & CEO, Vesselon, Inc. Last year Merck announced two Phase 3 fails of Keytruda that follow three others from last summer. Keynote-641 in Prostate Cancer and Keynote-789 in Non-Small Cell Lung Cancer fell short as did Keynote-412 (Head and Neck), Keynote-921 (Prostate) and LEAP-002 (Liver)…

Drug Delivery

2 min read

Drug Delivery

2 min read